BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22644735)

  • 1. Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.
    Hannan R; Zhang H; Wallecha A; Singh R; Liu L; Cohen P; Alfieri A; Rothman J; Guha C
    Cancer Immunol Immunother; 2012 Dec; 61(12):2227-38. PubMed ID: 22644735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Listeria monocytogenes based vaccine against prostate cancer.
    Shahabi V; Reyes-Reyes M; Wallecha A; Rivera S; Paterson Y; Maciag P
    Cancer Immunol Immunother; 2008 Sep; 57(9):1301-13. PubMed ID: 18273616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
    Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
    J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.
    Karan D
    Vaccine; 2017 Oct; 35(43):5794-5798. PubMed ID: 28939158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
    Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
    Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy.
    Wallecha A; Maciag PC; Rivera S; Paterson Y; Shahabi V
    Clin Vaccine Immunol; 2009 Jan; 16(1):96-103. PubMed ID: 19020110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer.
    Klyushnenkova EN; Kouiavskaia DV; Parkins CJ; Caposio P; Botto S; Alexander RB; Jarvis MA
    J Immunother; 2012 Jun; 35(5):390-9. PubMed ID: 22576344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
    Simons BW; Cannella F; Rowley DT; Viscidi RP
    Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.
    Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM
    Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.
    Riabov V; Tretyakova I; Alexander RB; Pushko P; Klyushnenkova EN
    Vaccine; 2015 Oct; 33(41):5386-5395. PubMed ID: 26319744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of interferon-γ-modified exosomal vaccine in prostate cancer.
    Shi X; Sun J; Li H; Lin H; Xie W; Li J; Tan W
    Prostate; 2020 Aug; 80(11):811-823. PubMed ID: 32427375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human.
    Shahabi V; Seavey MM; Maciag PC; Rivera S; Wallecha A
    Cancer Gene Ther; 2011 Jan; 18(1):53-62. PubMed ID: 20725099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
    Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
    Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
    Sewell DA; Shahabi V; Gunn GR; Pan ZK; Dominiecki ME; Paterson Y
    Cancer Res; 2004 Dec; 64(24):8821-5. PubMed ID: 15604239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a novel T cell-oriented vaccine using CTL/Th-hybrid epitope long peptide and biodegradable microparticles, against an intracellular bacterium.
    Tanaka K; Enomoto N; Uehara M; Furuhashi K; Sakurai S; Yasui H; Karayama M; Hozumi H; Suzuki Y; Fujisawa T; Inui N; Nakamura Y; Nagata T; Suda T
    Microbiol Immunol; 2020 Oct; 64(10):666-678. PubMed ID: 32786043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner.
    Harris TJ; Hipkiss EL; Borzillary S; Wada S; Grosso JF; Yen HR; Getnet D; Bruno TC; Goldberg MV; Pardoll DM; DeWeese TL; Drake CG
    Prostate; 2008 Sep; 68(12):1319-29. PubMed ID: 18561247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.